Butylidenephthalide antagonizes cromakalim-induced systolic pressure reduction in conscious normotensive rats

Chung Hung Shih, Yu Jing Lin, Chi Ming Chen, Wun-Chang Ko

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Butylidenephthalide (Bdph), a main constituent of Ligusticum chuanxiong Hort., was reported to have selective antianginal effect without changing blood pressure in conscious rat. Recently, we have observed that Bdph antagonized cromakalim, an ATP-dependent K+ channel opener, in guinea-pig trachea. Thus, we were interested in investigating whether Bdph at the dose without changing blood pressure antagonized cromakalim-induced systolic pressure reduction in conscious rats. Methods: Systolic arterial pressures of conscious rats were determined by using the indirect tail-cuff method. Results: Bdph (30 mg/kg, i.p.) did not affect baseline systolic pressure in conscious normotensive and spontaneous hypertensive rats. Bdph (30 mg/kg, i.p.) also did not affect log dose-response curves of prazosin, clonidine and Bay K 8644, a Ca2+ channel activator, in normotensive rats. However, Bdph (30 mg/kg, i.p.) similar to 4-aminopyridine (4-AP, 0.4 mg/kg, i.p.), a K+ channel blocker, non-parallelly but surmountably, and partially similar to glibenclamide (GBC, 10 mg/kg, i.v.), an ATP-sensitive K+ channel blocker, surmountably but not parallelly rightward shifted the log dose-systolic pressure reduction curve of cromakalim, an ATP-sensitive K+ channel opener, in normotensive rats, respectively. Discussion: The antagonistic effect of Bdph against cromakalim was similar to that of 4-AP, a K+ channel blocker of Kv1 family, and partially similar to that of GBC, an ATP-sensitive K+ channel blocker. Thus, Bdph may be a kind of K+ channel blockers, which have been reviewed to have a potential clinical use for Alzheimer disease. Indeed, Bdph has also been reported to reverse the deficits of inhibitory avoidance performance and improve memory in rats. Recently, 4-AP was reported to treat Episodic ataxia type 2 (EA2) which is a form of hereditary neurological disorder. Consistently, Bdph was recently reported to have antihyperglycemic activity in mice, since GBC is a powerful oral hypoglycemic drug. Conclusions: Bdph similar to 4-AP and partially similar to GBC may block Kv1 family and ATP-sensitive K+ channels in conscious normotensive rats.

Original languageEnglish
Article number344
JournalBMC Complementary and Alternative Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - Oct 5 2015

Fingerprint

Cromakalim
Blood Pressure
Adenosine Triphosphate
Hypoglycemic Agents
butylidenephthalide
Ligusticum
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
4-Aminopyridine
Glyburide
Prazosin
Clonidine
Trachea
Nervous System Diseases
Tail
Arterial Pressure
Alzheimer Disease
Guinea Pigs

Keywords

  • 4-Aminopiridine
  • ATP-sensitive K channels
  • Butylidenephthalide
  • Conscious normotensive rats
  • Cromakalim
  • K1 family of K channels

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Butylidenephthalide antagonizes cromakalim-induced systolic pressure reduction in conscious normotensive rats. / Shih, Chung Hung; Lin, Yu Jing; Chen, Chi Ming; Ko, Wun-Chang.

In: BMC Complementary and Alternative Medicine, Vol. 15, No. 1, 344, 05.10.2015.

Research output: Contribution to journalArticle

@article{c01fe1ecb22a4fd3aeaba8281143b3ce,
title = "Butylidenephthalide antagonizes cromakalim-induced systolic pressure reduction in conscious normotensive rats",
abstract = "Background: Butylidenephthalide (Bdph), a main constituent of Ligusticum chuanxiong Hort., was reported to have selective antianginal effect without changing blood pressure in conscious rat. Recently, we have observed that Bdph antagonized cromakalim, an ATP-dependent K+ channel opener, in guinea-pig trachea. Thus, we were interested in investigating whether Bdph at the dose without changing blood pressure antagonized cromakalim-induced systolic pressure reduction in conscious rats. Methods: Systolic arterial pressures of conscious rats were determined by using the indirect tail-cuff method. Results: Bdph (30 mg/kg, i.p.) did not affect baseline systolic pressure in conscious normotensive and spontaneous hypertensive rats. Bdph (30 mg/kg, i.p.) also did not affect log dose-response curves of prazosin, clonidine and Bay K 8644, a Ca2+ channel activator, in normotensive rats. However, Bdph (30 mg/kg, i.p.) similar to 4-aminopyridine (4-AP, 0.4 mg/kg, i.p.), a K+ channel blocker, non-parallelly but surmountably, and partially similar to glibenclamide (GBC, 10 mg/kg, i.v.), an ATP-sensitive K+ channel blocker, surmountably but not parallelly rightward shifted the log dose-systolic pressure reduction curve of cromakalim, an ATP-sensitive K+ channel opener, in normotensive rats, respectively. Discussion: The antagonistic effect of Bdph against cromakalim was similar to that of 4-AP, a K+ channel blocker of Kv1 family, and partially similar to that of GBC, an ATP-sensitive K+ channel blocker. Thus, Bdph may be a kind of K+ channel blockers, which have been reviewed to have a potential clinical use for Alzheimer disease. Indeed, Bdph has also been reported to reverse the deficits of inhibitory avoidance performance and improve memory in rats. Recently, 4-AP was reported to treat Episodic ataxia type 2 (EA2) which is a form of hereditary neurological disorder. Consistently, Bdph was recently reported to have antihyperglycemic activity in mice, since GBC is a powerful oral hypoglycemic drug. Conclusions: Bdph similar to 4-AP and partially similar to GBC may block Kv1 family and ATP-sensitive K+ channels in conscious normotensive rats.",
keywords = "4-Aminopiridine, ATP-sensitive K channels, Butylidenephthalide, Conscious normotensive rats, Cromakalim, K1 family of K channels",
author = "Shih, {Chung Hung} and Lin, {Yu Jing} and Chen, {Chi Ming} and Wun-Chang Ko",
year = "2015",
month = "10",
day = "5",
doi = "10.1186/s12906-015-0877-z",
language = "English",
volume = "15",
journal = "BMC Complementary and Alternative Medicine",
issn = "1472-6882",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Butylidenephthalide antagonizes cromakalim-induced systolic pressure reduction in conscious normotensive rats

AU - Shih, Chung Hung

AU - Lin, Yu Jing

AU - Chen, Chi Ming

AU - Ko, Wun-Chang

PY - 2015/10/5

Y1 - 2015/10/5

N2 - Background: Butylidenephthalide (Bdph), a main constituent of Ligusticum chuanxiong Hort., was reported to have selective antianginal effect without changing blood pressure in conscious rat. Recently, we have observed that Bdph antagonized cromakalim, an ATP-dependent K+ channel opener, in guinea-pig trachea. Thus, we were interested in investigating whether Bdph at the dose without changing blood pressure antagonized cromakalim-induced systolic pressure reduction in conscious rats. Methods: Systolic arterial pressures of conscious rats were determined by using the indirect tail-cuff method. Results: Bdph (30 mg/kg, i.p.) did not affect baseline systolic pressure in conscious normotensive and spontaneous hypertensive rats. Bdph (30 mg/kg, i.p.) also did not affect log dose-response curves of prazosin, clonidine and Bay K 8644, a Ca2+ channel activator, in normotensive rats. However, Bdph (30 mg/kg, i.p.) similar to 4-aminopyridine (4-AP, 0.4 mg/kg, i.p.), a K+ channel blocker, non-parallelly but surmountably, and partially similar to glibenclamide (GBC, 10 mg/kg, i.v.), an ATP-sensitive K+ channel blocker, surmountably but not parallelly rightward shifted the log dose-systolic pressure reduction curve of cromakalim, an ATP-sensitive K+ channel opener, in normotensive rats, respectively. Discussion: The antagonistic effect of Bdph against cromakalim was similar to that of 4-AP, a K+ channel blocker of Kv1 family, and partially similar to that of GBC, an ATP-sensitive K+ channel blocker. Thus, Bdph may be a kind of K+ channel blockers, which have been reviewed to have a potential clinical use for Alzheimer disease. Indeed, Bdph has also been reported to reverse the deficits of inhibitory avoidance performance and improve memory in rats. Recently, 4-AP was reported to treat Episodic ataxia type 2 (EA2) which is a form of hereditary neurological disorder. Consistently, Bdph was recently reported to have antihyperglycemic activity in mice, since GBC is a powerful oral hypoglycemic drug. Conclusions: Bdph similar to 4-AP and partially similar to GBC may block Kv1 family and ATP-sensitive K+ channels in conscious normotensive rats.

AB - Background: Butylidenephthalide (Bdph), a main constituent of Ligusticum chuanxiong Hort., was reported to have selective antianginal effect without changing blood pressure in conscious rat. Recently, we have observed that Bdph antagonized cromakalim, an ATP-dependent K+ channel opener, in guinea-pig trachea. Thus, we were interested in investigating whether Bdph at the dose without changing blood pressure antagonized cromakalim-induced systolic pressure reduction in conscious rats. Methods: Systolic arterial pressures of conscious rats were determined by using the indirect tail-cuff method. Results: Bdph (30 mg/kg, i.p.) did not affect baseline systolic pressure in conscious normotensive and spontaneous hypertensive rats. Bdph (30 mg/kg, i.p.) also did not affect log dose-response curves of prazosin, clonidine and Bay K 8644, a Ca2+ channel activator, in normotensive rats. However, Bdph (30 mg/kg, i.p.) similar to 4-aminopyridine (4-AP, 0.4 mg/kg, i.p.), a K+ channel blocker, non-parallelly but surmountably, and partially similar to glibenclamide (GBC, 10 mg/kg, i.v.), an ATP-sensitive K+ channel blocker, surmountably but not parallelly rightward shifted the log dose-systolic pressure reduction curve of cromakalim, an ATP-sensitive K+ channel opener, in normotensive rats, respectively. Discussion: The antagonistic effect of Bdph against cromakalim was similar to that of 4-AP, a K+ channel blocker of Kv1 family, and partially similar to that of GBC, an ATP-sensitive K+ channel blocker. Thus, Bdph may be a kind of K+ channel blockers, which have been reviewed to have a potential clinical use for Alzheimer disease. Indeed, Bdph has also been reported to reverse the deficits of inhibitory avoidance performance and improve memory in rats. Recently, 4-AP was reported to treat Episodic ataxia type 2 (EA2) which is a form of hereditary neurological disorder. Consistently, Bdph was recently reported to have antihyperglycemic activity in mice, since GBC is a powerful oral hypoglycemic drug. Conclusions: Bdph similar to 4-AP and partially similar to GBC may block Kv1 family and ATP-sensitive K+ channels in conscious normotensive rats.

KW - 4-Aminopiridine

KW - ATP-sensitive K channels

KW - Butylidenephthalide

KW - Conscious normotensive rats

KW - Cromakalim

KW - K1 family of K channels

UR - http://www.scopus.com/inward/record.url?scp=84946472202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946472202&partnerID=8YFLogxK

U2 - 10.1186/s12906-015-0877-z

DO - 10.1186/s12906-015-0877-z

M3 - Article

C2 - 26438097

AN - SCOPUS:84946472202

VL - 15

JO - BMC Complementary and Alternative Medicine

JF - BMC Complementary and Alternative Medicine

SN - 1472-6882

IS - 1

M1 - 344

ER -